A Nucleus-Targeting WT1 Antagonistic Peptide Encapsulated in Polymeric Nanomicelles Combats Refractory Chronic Myeloid Leukemia. Here, WT1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.